Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance.
Identifieur interne : 002E41 ( Ncbi/Curation ); précédent : 002E40; suivant : 002E42Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance.
Auteurs : Bontha V. Babu [Inde] ; Suchismita MishraSource :
- Transactions of the Royal Society of Tropical Medicine and Hygiene [ 1878-3503 ] ; 2008.
Descripteurs français
- KwdFr :
- Adulte, Attitude envers la santé, Enquêtes et questionnaires, Femelle, Filaricides (usage thérapeutique), Filariose lymphatique (), Filariose lymphatique (psychologie), Filariose lymphatique (traitement médicamenteux), Humains, Inde, Mâle, Observance du traitement médicamenteux (psychologie), Évaluation de programme ().
- MESH :
- psychologie : Filariose lymphatique, Observance du traitement médicamenteux.
- traitement médicamenteux : Filariose lymphatique.
- usage thérapeutique : Filaricides.
- Adulte, Attitude envers la santé, Enquêtes et questionnaires, Femelle, Filariose lymphatique, Humains, Inde, Mâle, Évaluation de programme.
- Wicri :
- geographic : Inde.
English descriptors
- KwdEn :
- Adult, Attitude to Health, Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (prevention & control), Elephantiasis, Filarial (psychology), Female, Filaricides (therapeutic use), Humans, India, Male, Medication Adherence (psychology), Program Evaluation (methods), Surveys and Questionnaires.
- MESH :
- chemical , therapeutic use : Filaricides.
- geographic : India.
- drug therapy : Elephantiasis, Filarial.
- methods : Program Evaluation.
- prevention & control : Elephantiasis, Filarial.
- psychology : Elephantiasis, Filarial, Medication Adherence.
- Adult, Attitude to Health, Female, Humans, Male, Surveys and Questionnaires.
Abstract
The present study aimed to identify the factors responsible for compliance and non-compliance of mass drug administration (MDA) under the programme to eliminate lymphatic filariasis (LF) from Orissa, India. It was based on both quantitative (through household MDA coverage survey) and qualitative data (through semi-structured interviews with heads of compliant and non-compliant households) collected during an MDA held in November 2005 in two districts of Orissa. In these districts, 83% of the eligible population received the drug (coverage) and only 49.5% people actually consumed the drug (compliance). Seventeen percent of the population did not even receive the drug. The predominant reason for not receiving the drug at household level was that the drug distributor did not visit the household, while the fear of adverse reactions is the predominant reason for not consuming it. The qualitative data revealed that the major contributor to taking the drug was the awareness that drug protects them from LF. Motivation by health workers was another reason for compliance. In many endemic areas, the issues related to non-compliance were taken casually during implementation. Hence, it is imperative to make the programme more efficient by addressing the issues linked to low compliance.
DOI: 10.1016/j.trstmh.2008.05.023
PubMed: 18632125
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003196
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :003196
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003196
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :002E41
Links to Exploration step
pubmed:18632125Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance.</title><author><name sortKey="Babu, Bontha V" sort="Babu, Bontha V" uniqKey="Babu B" first="Bontha V" last="Babu">Bontha V. Babu</name><affiliation wicri:level="1"><nlm:affiliation>Regional Medical Research Centre, Indian Council of Medical Research, Bhubaneswar 751 023, India. babubontha@gmail.com</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Regional Medical Research Centre, Indian Council of Medical Research, Bhubaneswar 751 023</wicri:regionArea><wicri:noRegion>Bhubaneswar 751 023</wicri:noRegion></affiliation></author><author><name sortKey="Mishra, Suchismita" sort="Mishra, Suchismita" uniqKey="Mishra S" first="Suchismita" last="Mishra">Suchismita Mishra</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="RBID">pubmed:18632125</idno><idno type="pmid">18632125</idno><idno type="doi">10.1016/j.trstmh.2008.05.023</idno><idno type="wicri:Area/PubMed/Corpus">003196</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003196</idno><idno type="wicri:Area/PubMed/Curation">003196</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003196</idno><idno type="wicri:Area/PubMed/Checkpoint">003196</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003196</idno><idno type="wicri:Area/Ncbi/Merge">002E41</idno><idno type="wicri:Area/Ncbi/Curation">002E41</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance.</title><author><name sortKey="Babu, Bontha V" sort="Babu, Bontha V" uniqKey="Babu B" first="Bontha V" last="Babu">Bontha V. Babu</name><affiliation wicri:level="1"><nlm:affiliation>Regional Medical Research Centre, Indian Council of Medical Research, Bhubaneswar 751 023, India. babubontha@gmail.com</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Regional Medical Research Centre, Indian Council of Medical Research, Bhubaneswar 751 023</wicri:regionArea><wicri:noRegion>Bhubaneswar 751 023</wicri:noRegion></affiliation></author><author><name sortKey="Mishra, Suchismita" sort="Mishra, Suchismita" uniqKey="Mishra S" first="Suchismita" last="Mishra">Suchismita Mishra</name></author></analytic><series><title level="j">Transactions of the Royal Society of Tropical Medicine and Hygiene</title><idno type="eISSN">1878-3503</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Attitude to Health</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (prevention & control)</term><term>Elephantiasis, Filarial (psychology)</term><term>Female</term><term>Filaricides (therapeutic use)</term><term>Humans</term><term>India</term><term>Male</term><term>Medication Adherence (psychology)</term><term>Program Evaluation (methods)</term><term>Surveys and Questionnaires</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Attitude envers la santé</term><term>Enquêtes et questionnaires</term><term>Femelle</term><term>Filaricides (usage thérapeutique)</term><term>Filariose lymphatique ()</term><term>Filariose lymphatique (psychologie)</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Humains</term><term>Inde</term><term>Mâle</term><term>Observance du traitement médicamenteux (psychologie)</term><term>Évaluation de programme ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Filaricides</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>India</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Program Evaluation</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="psychologie" xml:lang="fr"><term>Filariose lymphatique</term><term>Observance du traitement médicamenteux</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Medication Adherence</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Filaricides</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Attitude to Health</term><term>Female</term><term>Humans</term><term>Male</term><term>Surveys and Questionnaires</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Attitude envers la santé</term><term>Enquêtes et questionnaires</term><term>Femelle</term><term>Filariose lymphatique</term><term>Humains</term><term>Inde</term><term>Mâle</term><term>Évaluation de programme</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Inde</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The present study aimed to identify the factors responsible for compliance and non-compliance of mass drug administration (MDA) under the programme to eliminate lymphatic filariasis (LF) from Orissa, India. It was based on both quantitative (through household MDA coverage survey) and qualitative data (through semi-structured interviews with heads of compliant and non-compliant households) collected during an MDA held in November 2005 in two districts of Orissa. In these districts, 83% of the eligible population received the drug (coverage) and only 49.5% people actually consumed the drug (compliance). Seventeen percent of the population did not even receive the drug. The predominant reason for not receiving the drug at household level was that the drug distributor did not visit the household, while the fear of adverse reactions is the predominant reason for not consuming it. The qualitative data revealed that the major contributor to taking the drug was the awareness that drug protects them from LF. Motivation by health workers was another reason for compliance. In many endemic areas, the issues related to non-compliance were taken casually during implementation. Hence, it is imperative to make the programme more efficient by addressing the issues linked to low compliance.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E41 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 002E41 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:18632125
|texte= Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:18632125" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |